California Proceeds With Manufacturing Its Own Generics
As Generic Drug Pricing Bill Gets Approval
With the legislature’s green light on California’s Generic Drug Pricing Bill, the state aims to manufacture generics while addressing shortages in the prescription drug market, expanding access to life-saving generic prescription drugs and improving patient health outcomes and overall public health.
You may also be interested in...
California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.
Teva has completed its portfolio of digital inhalers by launching a further two products, AirDuo Digihaler (fluticasone propionate/salmeterol) and ArmonAir Digihaler (fluticasone propionate), in the US. The pair join the firm’s previously launched ProAir Digihaler (albuterol sulfate).
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.